Clinical Trials, Phase I as Topic

• 

  Subject Areas on Research

  • A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma. 
  • A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. 
  • A hybrid Bayesian adaptive design for dose response trials. 
  • A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. 
  • A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies. 
  • A systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants. 
  • ALSUntangled No. 35: Hyperbaric Oxygen Therapy. 
  • Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. 
  • Adaptive clinical trial design. 
  • Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. 
  • An exploration of relative health stock in advanced cancer patients. 
  • An intervention to improve cancer patients' understanding of early-phase clinical trials. 
  • An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral. 
  • Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. 
  • Antiretroviral therapy: evaluating the new era in HIV treatment. 
  • Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. 
  • Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. 
  • CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. 
  • Cabozantinib in genitourinary malignancies. 
  • Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. 
  • Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. 
  • Clinical uses of pegylated pharmaceuticals in oncology. 
  • Combining classification trees using MLE 
  • Comment regarding benefit in phase 1 oncology trials. 
  • Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. 
  • Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer. 
  • Consent forms and the therapeutic misconception: the example of gene transfer research. 
  • Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. 
  • Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. 
  • Eptifibatide in percutaneous coronary intervention. A review. 
  • Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials. 
  • Evaluation of ventricular arrhythmias in early clinical pharmacology trials and potential consequences for later development. 
  • Everolimus in colorectal cancer. 
  • Extending principles learned in model systems to clinical trials design. 
  • Future directions in regional treatment strategies for melanoma and sarcoma. 
  • GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. 
  • Genome-editing Technologies for Gene and Cell Therapy. 
  • HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. 
  • HIV vaccines. Viral envelope fails to deliver? 
  • Inhibition of poxvirus growth by Terameprocol, a methylated derivative of nordihydroguaiaretic acid. 
  • Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms. 
  • Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512). 
  • Live-attenuated Vaccines Prevent Respiratory Syncytial Virus-associated Illness in Young Children. 
  • Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent. 
  • Mammalian target of rapamycin inhibition. 
  • Marketing drugs too early in testing. 
  • Modulation of the Coagulation Cascade Using Aptamers. 
  • Monoclonal antibodies for brain tumour treatment. 
  • New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. 
  • Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis. 
  • Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception. 
  • Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. 
  • Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines. 
  • Phase I participants' views of quality of life and trial participation burdens. 
  • Phase I studies with the novel nucleoside analog gemcitabine. 
  • Phase I trial design: are new methodologies being put into practice? 
  • Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). 
  • Plasma Metabolites and Risk of Radiation-induced Esophagitis: A Secondary Analysis from a Prospective Study. 
  • Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors. 
  • Prasugrel, a third generation thienopyridine and potent platelet inhibitor. 
  • Prasugrel. 
  • Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. 
  • Predictors of Delayed Cerebral Ischemia in Patients with Aneurysmal Subarachnoid Hemorrhage with Asymptomatic Angiographic Vasospasm on Admission. 
  • Prevalence and impact of correlative science in breast cancer phase II trials. 
  • Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial. 
  • Prostate cancer gene therapy. 
  • Quality of potent Mn porphyrin-based SOD mimics and peroxynitrite scavengers for pre-clinical mechanistic/therapeutic purposes. 
  • RNA as performance-enhancers for dendritic cells. 
  • Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. 
  • Recommendations for clinical trial evaluation of acute stroke therapies. 
  • Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question? 
  • Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. 
  • Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer. 
  • Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial. 
  • Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report. 
  • Technology evaluation: Rexin-G, Epeius Biotechnologies. 
  • The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial. 
  • The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. 
  • The role of amifostine as a radioprotector. 
  • Therapeutic misconception in early phase gene transfer trials. 
  • Uncertain benefit: investigators' views and communications in early phase gene transfer trials. 
  • Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials. 
  • Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. 
  • Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. 
  • Using immunotherapy to target EGF in patients with NSCLC. 
  • Varieties of uncertainty and the validity of informed consent. 
  • Vinorelbine (Navelbine) in non-small cell lung cancer: future directions. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Thomas, Melanie Byrne, Associate Professor of Medicine, Medicine, Medical Oncology
  • West, Vivian L, Clinical Associate in the School of Nursing, School of Nursing